龙胆紫 | 765266-81-7

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 消毒防腐药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 龙胆紫
• 中文别名: 甲紫；甲基青莲；甲基紫6B；甲基紫；盐酸甲基紫罗兰；甲基紫2B；碱性紫1
• 英文名称: N-(4-{bis[4-(dimethylamino)phenyl]methylidene}cyclohexa-2,5-dien-1-ylidene)methanaminium
• 英文别名: [4-[[4-(dimethylamino)phenyl]-[4-(methylamino)phenyl]methylidene]cyclohexa-2,5-dien-1-ylidene]-dimethylazanium
• CAS: 765266-81-7；8004-87-3
• 化学式: C24H28N3+
• 分子量: 358.5
• InChiKey: AMPCGOAFZFKBGH-UHFFFAOYSA-O

物化性质

• 熔点：
  137°C
• 沸点：
  548.19°C (rough estimate)
• 密度：
  1.0395 (rough estimate)
• 溶解度：
  易溶于水、乙醇、氯仿；不溶于乙醚、二甲苯
• 最大波长(λmax)：
  584nm

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  18.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• TSCA：
  Yes
• 危险等级：
  9

制备方法与用途

苯胺紫

简介 苯胺紫是最早由人工合成的紫色染料。与传统从骨螺科海螺中提取“贝紫色”相比，人工合成极大地降低了成本。“贝紫色”的生产需要大量采集海螺，成本极高，因此紫色也成为了上流社会身份象征。古希腊语中的"Porphura"即为紫罗兰色，“Purple”的词源亦源于此。

应用 在医药领域，龙胆紫用作局部抗感染药和杀菌药。其10g/L水溶液常用于制作紫药水。工业上，苯胺紫可用作染料，能将羊毛、蚕丝及经鞣酸处理的棉制品染成紫色，并应用于染纸张、皮革、制墨水、打印色、复写纸等。

理化性质 甲紫（龙胆紫）为碱性染料，由氯化四甲基—氯化五甲基—和氯化六甲基—副玫瑰苯胺混合而成。其为深绿紫色粉末或带金属光泽的碎片，略具臭味，溶于水、乙醇及氯仿中，但不溶于乙醚。通过二甲基替苯胺、苯酚、食盐与硫酸铜共热制得。用于染羊毛、蚕丝和经鞣酸处理的棉制品，也可用于染麦秆、纸张、皮革、脂肪、羽毛以及制作墨水、打印色、复写纸等。医药上主要用作消毒防腐剂，其10g/L水溶液即为常用的紫药水。适用于革兰氏阳性细菌和霉菌感染、粘膜及皮肤溃疡治疗，对烧伤亦有效，内服可治蛲虫病。

药理作用 甲紫阳离子与细菌蛋白质的羟基结合影响细菌代谢，产生抑菌效果。其对革兰阳性菌尤其是葡萄球菌和白喉杆菌作用显著，并对铜绿假单胞菌及白色念珠菌、表皮癣菌等真菌有杀菌作用，同时对蛲虫亦有效。该物质还可与坏死组织结合形成保护膜，起到收敛效果，且无明显刺激性。

主要用途和用法 1%～3%溶液用于治疗皮肤、黏膜创伤及溃疡：取龙胆紫（甲紫或结晶紫）1～3克溶于适量乙醇中，加蒸馏水至100毫升。 2%～10%软膏剂用于治疗烫伤和烧伤：取甲紫（龙胆紫、结晶紫）2～10克与90～98克凡士林均匀混合即可。此外，该药物也可用于足癣继发感染、脓皮病的治疗。 对于念珠菌性口腔炎及外阴阴道炎，采用1%或2%溶液剂涂抹。

用途 用作生物染色剂

用途 还可作为酸碱指示剂以及检定汞、银及锡等金属离子。

生产方法 二甲基苯胺在硫酸铜、苯酚和盐的作用下进行氧化缩合，再经碱性转化、酸性转化、盐析及后处理得到碱性紫5BN，进一步精制得甲紫。

文献信息

• COLORING AGENTS AND METHODS OF USE THEREOF
  申请人：Living Proof, Inc.

  公开号：US20160106648A1

  公开（公告）日：2016-04-21

  Dyes, compositions comprising dyes and methods for using the same are provided.

  染料、包含染料的组合物以及使用这些染料的方法。
• Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent
  申请人：Fuisz Richard C.

  公开号：US20110182807A1

  公开（公告）日：2011-07-28

  A dosage form includes a dose of at least one bioactive agent and a substance that can be readily confirmed by medical personnel to determine if the patient is compliant with taking the dosage form. The substance is at least one member selected from the group consisting of (a) a material incorporated in the dose in a manner that when the dosage form is properly administered is by itself or when combined with a reagent visible in the buccal, vaginal, nasal, rectal, aural, ophthalmic or ostomic cavity of a patient or an excretion of a patient in normal light or when exposed to a special frequency light source, (b) a material that is by itself not readily visible in the buccal, vaginal, nasal, rectal, aural, ophthalmic or ostomic cavity of a patient or an excretion of a patient in normal light but by itself or when combined with a reagent is readily visible when exposed to a special frequency light source, (c) a material that is by itself not readily visible in the buccal, vaginal, nasal, rectal, aural, ophthalmic or ostomic cavity of a patient or an excretion of a patient in normal light but when combined with a reagent is readily visible in normal light and (d) a material that is by itself not readily visible in the buccal, vaginal, nasal, rectal, aural, ophthalmic or ostomic cavity of a patient or an excretion of a patient in normal light but by itself or when combined with a reagent is readily detected by a non-visual detection method.
• METHOD AND DOSAGE FORM TO CONFIRM COMPLIANT USE OF A BIOACTIVE AGENT
  申请人：FUISZ Richard C.

  公开号：US20110182824A1

  公开（公告）日：2011-07-28

  A dosage form includes a dose of at least one bioactive agent and a substance that is visible to a normal light or to a special light source in the buccal, nasal, vaginal, rectal or ostomic cavity of a patient in order for medical personnel to determine if the patient is being compliant with taking medication or that a person is not truthful in denial of taking medication. The substance is either coating the at least one bioactive agent or intermixed with the at least one bioactive agent in a delivering body, and leaves behind a stain in the cavity for a predetermined period for compliance/abuse assessment.
• DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY
  申请人：Hong Rui

  公开号：US20130122516A1

  公开（公告）日：2013-05-16

  Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section.
• SIGNALING CONJUGATES AND METHODS OF USE
  申请人：VENTANA MEDICAL SYSTEMS, INC.

  公开号：US20130260379A1

  公开（公告）日：2013-10-03

  Disclosed herein are embodiments of a signaling conjugate, embodiments of a method of using the signaling conjugates, and embodiments of a kit comprising the signaling conjugate. The disclosed signaling conjugate comprises a latent reactive moiety and a chromogenic moiety that may further comprise a linker suitable for coupling the latent reactive moiety to the chromogenic moiety. The signaling conjugate may be used to detect one or more targets in a biological sample and are capable of being covalently deposited directly on or proximally to the target. Particular disclosed embodiments of the method of using the signaling conjugate comprise multiplexing methods.

表征谱图